Evogene (NASDAQ:EVGN) announced a fundamental strategic refocusing alongside its fourth-quarter and full-year 2025 financial results, moving to concentrate its resources on its proprietary ChemPass AI™ tech-engine.
The shift marks a transition from a broad multi-subsidiary model to a streamlined focus on high-impact discovery for the pharmaceutical and agricultural industries.
For the fiscal year ended December 31, 2025, the Rehovot, Israel-based company reported total revenue of approximately $3.9 million.
While the company recorded an operating loss of $14 million, its net loss for the year improved to $7.8 million, aided by a $6.4 million gain from the divestment of its stake in Lavie Bio to ICL Group.
This capital-efficient strategy was further supported by a reduction in operating expenses to approximately $13.8 million, down from prior years as the company resized its workforce and discontinued non-core activities.
The core of Evogene’s 2026 outlook is the ChemPass AI™ platform, which utilizes a generative AI foundation model trained on a universe of 38 billion molecules.
In February 2026, the company expanded its partnership with Google Cloud to integrate advanced "AI agents" into the engine, aiming to automate complex discovery workflows and accelerate the path to market-ready small molecules.
Current collaborations with partners like Bayer and Corteva, as well as new academic partnerships for cancer and inflammatory research, underscore the platform’s translational potential.
Evogene ended the year with consolidated cash, equivalents, and short-term bank deposits of approximately $13.0 million.
This liquidity was bolstered in February 2026 by $3.4 million in gross proceeds from a warrant exercise inducement.